Literature DB >> 10477587

CD40-CD40 ligand costimulation is required for generating antiviral CD4 T cell responses but is dispensable for CD8 T cell responses.

J K Whitmire1, R A Flavell, I S Grewal, C P Larsen, T C Pearson, R Ahmed.   

Abstract

This study documents a striking dichotomy between CD4 and CD8 T cells in terms of their requirements for CD40-CD40 ligand (CD40L) costimulation. CD40L-deficient (-/-) mice made potent virus-specific CD8 T cell responses to dominant as well as subdominant epitopes following infection with lymphocytic choriomeningitis virus. In contrast, in the very same mice, virus-specific CD4 T cell responses were severely compromised. There were 10-fold fewer virus-specific CD4 T cells in CD40L-/- mice compared with those in CD40L+/+ mice, and this inhibition was seen for both Th1 (IFN-gamma, IL-2) and Th2 (IL-4) responses. An in vivo functional consequence of this Th cell defect was the inability of CD40L-/- mice to control a chronic lymphocytic choriomeningitis virus infection. This study highlights the importance of CD40-CD40L interactions in generating virus-specific CD4 T cell responses and in resolving chronic viral infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10477587

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

1.  High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection.

Authors:  J D Ahlers; I M Belyakov; E K Thomas; J A Berzofsky
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

2.  Roles for CD40, B7 and major histocompatibility complex in induction of enhanced immunity by cryptococcal polysaccharide-pulsed antigen-presenting cells.

Authors:  Rebecca Blackstock
Journal:  Immunology       Date:  2003-02       Impact factor: 7.397

3.  A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L.

Authors:  Jeffrey D Ahlers; Igor M Belyakov; Masaki Terabe; Rima Koka; Debra D Donaldson; Elaine K Thomas; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-13       Impact factor: 11.205

4.  Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function.

Authors:  Amy D H Doody; Joseph T Kovalchin; Marianne A Mihalyo; Adam T Hagymasi; Charles G Drake; Adam J Adler
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

Review 5.  Memory CD8 T-cell differentiation during viral infection.

Authors:  E John Wherry; Rafi Ahmed
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

6.  CD70 expression by dendritic cells plays a critical role in the immunogenicity of CD40-independent, CD4+ T cell-dependent, licensed CD8+ T cell responses.

Authors:  Katherine E Van Deusen; Rohan Rajapakse; Timothy N J Bullock
Journal:  J Leukoc Biol       Date:  2009-12-01       Impact factor: 4.962

7.  Quantitative PCR technique for detecting lymphocytic choriomeningitis virus in vivo.

Authors:  Megan M McCausland; Shane Crotty
Journal:  J Virol Methods       Date:  2007-10-17       Impact factor: 2.014

8.  The mouse cytomegalovirus glycoprotein m155 inhibits CD40 expression and restricts CD4 T cell responses.

Authors:  Andrea I Loewendorf; Lars Steinbrueck; Christoph Peter; Andreas Busche; Chris A Benedict; Penelope C Kay-Jackson
Journal:  J Virol       Date:  2011-03-16       Impact factor: 5.103

Review 9.  Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease.

Authors:  John Attanasio; E John Wherry
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

10.  CD154 signaling regulates the Th1 response to herpes simplex virus-1 and inflammation in infected corneas.

Authors:  Min Xu; Andrew J Lepisto; Robert L Hendricks
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.